By the 1990s, we began our Research and Development (R&D) project. In the last decade we saw the birth of our own medicines. We are building our way into research inspired by our strong motivation: Keeping life in mind.
Our R&D centre in Portugal is staffed by international teams of highly qualified people. It comprises chemists, pharmacologists, biochemists, physicians and pharmacists, all of whom are dedicated to finding new drugs, in two major areas of research: neurosciences and cardiology.
Our scientific team centralizes all the areas involved in the process of finding new medicinal products: chemical, pharmacological and clinical investigation. We collaborate with investigators and scientists from universities, industry and research centers to deliver the best solutions to health professionals, patients and their families.
Recently, BIAL established a new affiliate in the United States of America, BIAL Biotech Investments Inc (BIAL Biotech). BIAL Biotech is a research center of excellence for the development of genetically-defined Parkinson’s disease therapeutics. With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's Disease, where the company already has a significant market position.
We see Research and Development as a strategic area for the group. We are pledged to manage knowledge and innovation to develop, in a systematic and sustained manner, internationally competitive therapeutic solutions that merit acceptance from the scientific community, regulatory authorities and the market and which, as a consequence deliver value to the company and to its shareholders, employees, medical fraternity, consumers and other business partners.
This commitment will be fulfilled, throughout the Company, by adhering to some principles:
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.